Interesting to see this on HN. I was part of the research group which published this back in 2015 [1], I think we were the second group worldwide to publish this.
So, first off, this is not new. The linked publication here mainly seems to be explaining a potential mechanism of how it might happen.
Some quick notes to aid in a constructive discussion - bear with me, it's been a while and I've left research and since worked as a software developer, chuckle:
- Different gadolinium agents have vastly different "buildup" characteristics - some are better, some are worse. Biochemically, the ones where the gadolinium was trapped in harder "complexes", those were more stable (less accumulation). I suck at biochemistry, so all of those words may be wrong.
- If you'd want to over-engineer this, you could indeed select your MRI hospital / practice based on which gadolinium agent they use.
- Unless you're getting a ton of MRIs (think multiple sclerosis monitoring etc.), you probably won't be affected.
- Most MRIs are without contrast agent anyway, so you probably won't be affected.
- The last I heard was that the clinical implications were still being investigated - like, yeah, you do see a buildup of gadolinium in patients who 1) get certain gadolinium agents and 2) have a ton of MRIs, but what does that mean they'll suffer any clinical consequences from this? Not sure. I heard that there was a paper (.. somewhere) which at least showed a correlation with worse MS outcomes of people who had a high buildup, but then again, cause-effect here is not clear as people with worse MS tend to have more MRIs, too (correlation != causation).
[1] https://pubs.rsna.org/doi/full/10.1148/radiol.2015150337